Evidence map›Paper›PMID 26702783›Full record

ArticleNuclear medicine and biology2016

Radiosynthesis of clinical doses of ⁶⁸Ga-DOTATATE (GalioMedix™) and validation of organic-matrix-based ⁶⁸Ge/⁶⁸Ga generators.

Izabela Tworowska, David Ranganathan, Sanjay Thamake, Ebrahim Delpassand, Alireza Mojtahedi, Michael K Schultz, Konstantin Zhernosekov, Sebastian Marx

Open access · greenAbstract readValidation Study
In one paragraph

Article in Nuclear medicine and biology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
2.4field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 33 citations in OpenAlex.

  1. Review
  2. Article
  3. Article
  4. In Vivo Evaluation ofPharmaceutics · 2024
    Article
  5. A personal acquisition time regimen ofCancer imaging : the official publication of the International Cancer Imaging Society · 2022
    Article
  6. Automated synthesis of [EJNMMI radiopharmacy and chemistry · 2022
    Article
  7. Article
  8. Peptide-BasedMolecular pharmaceutics · 2018
    Article
  9. Preliminary PET/CT Imaging with Somatostatin Analogs [Molecular imaging and biology · 2017
    Article
  10. Development of aACS omega · 2017
    Article
  11. Installation and Optimization ofIndian journal of nuclear medicine : IJNM : the official journal of the Society of Nuclear Medicine, India
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 3 institutions in 2 countries.

Izabela TworowskaRadioMedix Inc., Houston, TX, USA. Electronic address: itworowska@radiomedix.com.
David RanganathanRadioMedix Inc., Houston, TX, USA.
Sanjay ThamakeRadioMedix Inc., Houston, TX, USA.
Ebrahim DelpassandRadioMedix Inc., Houston, TX, USA.
Alireza MojtahediRadioMedix Inc., Houston, TX, USA.
Michael K SchultzDepartment of Radiology, University of Iowa, Iowa City, IA USA; Department of Radiation Oncology, University of Iowa, Iowa City, IA USA.
Konstantin ZhernosekovITM Isotopen Technologien München AG, Garching, Germany.
Sebastian MarxITM Isotopen Technologien München AG, Garching, Germany.
RadioMedix (United States) · USIsotopen Technologien München (Germany) · DEUniversity of Iowa · US

Funding

Viral VectorP30CA086862 · NCI · UNIVERSITY OF IOWA · PI Douglas Robert Spitz · 2000 to 2026
$70.0M
Project 4: New Approaches to Improving the Effectiveness of Radionuclide Targeted Treatments in Neuroendocrine TumorsP50CA174521 · NCI · UNIVERSITY OF IOWA · PI ODORISIO, THOMAS · 2015 to 2021
$13.2M
Mitochondrial Targeted Metastatic Melanoma TherapyK25CA172218 · NCI · UNIVERSITY OF IOWA · PI SCHULTZ, MICHAEL KING · 2013 to 2017
$753k
NCI NIH HHS K25 CA172218NCI NIH HHS P50 CA174521
6 · The paper itself

Abstract

introduction68Ga-DOTATATE is a radiolabeled peptide-based agonist that targets somatostatin receptors overexpressed in neuroendocrine tumors. Here, we present our results on validation of organic matrix 68Ge/68Ga generators (ITG GmbH) applied for radiosynthesis of the clinical doses of 68Ga-DOTATATE (GalioMedixTM).

methodsThe clinical grade of DOTATATE (25 μg±5 μg) compounded in 1 M NaOAc at pH=5.5 was labeled manually with 514±218 MBq (13.89±5.9 mCi) of 68Ga eluate in 0.05 N HCl at 95°C for 10 min. The radiochemical purity of the final dose was validated using radio-TLC. The quality control of clinical doses included tests of their osmolarity, endotoxin level, radionuclide identity, filter integrity, pH, sterility and 68Ge breakthrough.

resultsThe final dose of 272±126 MBq (7.35±3.4 mCi) of 68Ga-DOTATATE was produced with a radiochemical yield (RCY) of 99%±1%. The total time required for completion of radiolabeling and quality control averaged approximately 35 min. This resulted in delivery of 50%±7% of 68Ga-DOTATATE at the time of calibration (not decay corrected).

conclusions68Ga eluted from the generator was directly applied for labeling of DOTA-peptide with no additional pre-concentration or pre-purification of isotope. The low acidity of 68Ga eluate allows for facile synthesis of clinical doses with radiochemical and radionuclide purity higher than 98% and average activity of 272±126 MBq (7.3±3 mCi). There is no need for post-labeling C18 Sep-Pak purification of final doses of radiotracer. Advances in knowledge and implications for patient care. The clinical interest in validation of 68Galabeled agents has increased in the past years due to availability of generators from different vendors (Eckert-Ziegler, ITG, iThemba), favorable approach of U.S. FDA agency to initiate clinical trials, and collaboration of U.S. centers with leading EU clinical sites. The list of 68Ga-labeled tracers evaluated in clinical studies should growth because of the sensitivity of PET technique, the simplicity of the shakebake approach for the dose preparation and reliability of 68Ge/68Ga generators. Our studies have confirmed the reproducible elution profile, and high reliability of ITG GmbH generators required for routine doses preparation according to FDA recommendations.

Indexed as

Radiation DosageRadioisotopesChemistry Techniques, SyntheticGermaniumHumansIon ExchangeOrganometallic CompoundsRadiochemistrygallium Ga 68 dotatateGermaniumOrganometallic CompoundsRadioisotopes(68)Ga-DOTATATE(68)Ge/(68)Ga generator(68)Ge breakthroughNeuroendocrine tumorsPositron emission tomography (PET)Quality control of PET-tracers doses

Identifiers

PMID26702783
PMCPMC5538886
OpenAlexW2180249406

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.